The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
PTC Therapeutics Inc (NASDAQ: PTCT) closed the day trading at $77.25 down -0.76% from the previous closing price of $77.85. In other words, the price has decreased by -$0.76 from its previous closing price. On the day, 0.82 million shares were traded. PTCT stock price reached its highest trading level at $78.68 during the session, while it also had its lowest trading level at $76.5401.
Ratios:
For a better understanding of PTCT, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.67 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8.80. For the most recent quarter (mrq), Quick Ratio is recorded 2.26 and its Current Ratio is at 2.32.
On October 20, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $73.
On June 17, 2025, Truist started tracking the stock assigning a Buy rating and target price of $80.Truist initiated its Buy rating on June 17, 2025, with a $80 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 03 ’25 when Reeve Emma sold 733 shares for $78.62 per share. The transaction valued at 57,628 led to the insider holds 6,666 shares of the business.
Klein Matthew B. sold 3,428 shares of PTCT for $271,052 on Dec 02 ’25. The CHIEF EXECUTIVE OFFICER now owns 349,964 shares after completing the transaction at $79.07 per share. On Dec 03 ’25, another insider, Reeve Emma, who serves as the Director of the company, bought 733 shares for $78.62 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTCT now has a Market Capitalization of 6202672640 and an Enterprise Value of 6987409920. As of this moment, PTC’s Price-to-Earnings (P/E) ratio for their current fiscal year is 9.03. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.49. Its current Enterprise Value per Revenue stands at 3.927 whereas that against EBITDA is 7.317.
Stock Price History:
The Beta on a monthly basis for PTCT is 0.49, which has changed by 0.6074698 over the last 52 weeks, in comparison to a change of 0.13506866 over the same period for the S&P500. Over the past 52 weeks, PTCT has reached a high of $87.50, while it has fallen to a 52-week low of $35.95. The 50-Day Moving Average of the stock is 9.32%, while the 200-Day Moving Average is calculated to be 39.48%.
Shares Statistics:
Over the past 3-months, PTCT traded about 1.56M shares per day on average, while over the past 10 days, PTCT traded about 3354240 shares per day. A total of 79.93M shares are outstanding, with a floating share count of 77.16M. Insiders hold about 3.90% of the company’s shares, while institutions hold 102.98% stake in the company. Shares short for PTCT as of 1763078400 were 9418915 with a Short Ratio of 6.04, compared to 1760486400 on 7816416. Therefore, it implies a Short% of Shares Outstanding of 9418915 and a Short% of Float of 13.459999999999999.
Earnings Estimates
A detailed examination of PTC Therapeutics Inc (PTCT) is currently in progress, with 6.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$1.09, with high estimates of -$1.03 and low estimates of -$1.14.
Analysts are recommending an EPS of between $10.66 and $5.52 for the fiscal current year, implying an average EPS of $8.82. EPS for the following year is -$0.73, with 7.0 analysts recommending between $1.25 and -$3.48.
Revenue Estimates
12 analysts predict $236.87M in revenue for. The current quarter. It ranges from a high estimate of $385.47M to a low estimate of $167.67M. As of. The current estimate, PTC Therapeutics Inc’s year-ago sales were $213.17MFor the next quarter, 12 analysts are estimating revenue of $194.19M. There is a high estimate of $259M for the next quarter, whereas the lowest estimate is $169M.
A total of 14 analysts have provided revenue estimates for PTCT’s current fiscal year. The highest revenue estimate was $1.95B, while the lowest revenue estimate was $1.72B, resulting in an average revenue estimate of $1.8B. In the same quarter a year ago, actual revenue was $806.78MBased on 14 analysts’ estimates, the company’s revenue will be $971.98M in the next fiscal year. The high estimate is $1.18B and the low estimate is $804.3M.
